Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
Status:
Terminated
Trial end date:
2019-11-11
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of axitinib and bosutinib and
how well they work in treating patients with chronic, accelerated, or blastic phase chronic
myeloid leukemia. Axitinib and bosutinib may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth.